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Abstract
Background—Integrating antenatal care (ANC) and HIV care may improve uptake and 
retention in services along the prevention of mother-to-child transmission (PMTCT) cascade. The 
current study aimed to determine if integration of HIV services into ANC settings improves 
PMTCT service utilization outcomes.
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Methods—ANC clinics in rural Kenya were randomized to integrated (6 clinics, 569 women) or 
non-integrated (6 clinics, 603 women) services. Intervention clinics provided all HIV services, 
including highly active antiretroviral therapy (HAART), while control clinics provided PMTCT 
services but referred women to HIV care clinics within the same facility. PMTCT utilization 
outcomes among HIV-infected women (maternal HIV care enrollment, HAART initiation, and 3-
month infant HIV testing uptake) were compared using generalized estimating equations and Cox 
regression.
Results—HIV care enrollment was higher in intervention compared to control clinics (69% 
versus 36%, Odds Ratio (OR)=3.94, 95% Confidence Interval (CI): 1.14–13.63). Median time to 
enrollment was significantly shorter among intervention arm women (0 versus 8 days, Hazard 
Ratio (HR)=2.20, 95% CI: 1.62–3.01). Eligible women in the intervention arm were more likely to 
initiate HAART (40% versus 17%, OR=3.22, 95% CI: 1.81–5.72). Infant testing was more 
common in the intervention arm (25% versus 18%), however not statistically different. No 
significant differences were detected in postnatal service uptake or maternal retention.
Conclusions—Service integration increased maternal HIV care enrollment and HAART uptake. 
However, PMTCT utilization outcomes were still suboptimal, and postnatal service utilization 
remained poor in both study arms. Further improvements in the PMTCT cascade will require 
additional research and interventions.
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Introduction
Effective prevention of mother-to-child transmission (PMTCT) programs can reduce MTCT 
from 15–40% to 1%.1–3 However, achieving this rate has been challenging in sub-Saharan 
Africa (SSA),4–7 and PMTCT service coverage remains below 50%.6,8 Low coverage may 
be partially explained by the initial introduction of PMTCT programs as stand-alone vertical 
programs.9–11 In addition, PMTCT interventions create significant additional work for staff 
in healthcare systems already suffering from insufficient human, financial, and structural 
resources.12 Thus, PMTCT implementation is suboptimal and has not produced the expected 
reduction in MTCT rates.10,13
In addition to health system challenges, PMTCT programs in SSA experience high rates of 
maternal and infant loss-to-follow-up (LTFU) at each step of the service delivery cascade; 
i.e., from HIV testing and counseling (HTC), initiation of antiretrovirals (ARVs) for 
PMTCT prophylaxis or maternal health, and linkage to maternal and pediatric HIV care 
services for follow-up.8,14,15 Recently, high levels of antenatal HTC and ARV prophylaxis 
coverage have been achieved in many countries,16,17 and the largest drop-offs in the 
PMTCT cascade occur with linkage to and retention in HIV care services.18–21
In Kenya, almost all pregnant women attend an antenatal care (ANC) clinic at least once 
during their pregnancy (94%)22 and receive routine opt-out HTC. However, 2009 national 
statistics showed that only 79% of HIV+ pregnant women received ARV prophylaxis and 
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only 35% of HIV-exposed infants received early infant diagnostic testing at 6 weeks.23 
Furthermore, PMTCT services referred only 56% of HIV+ pregnant women to HIV 
treatment programs.24 Consequently the national MTCT rate has been estimated to be as 
high as 10.7%.25
PMTCT service integration with other health services targeting women and children is 
recommended as a key strategy to improve maternal and child health in low-resource 
settings with high HIV burdens.8,26,2,27 Integration is posited to 1) improve uptake of and 
retention in services, 2) reduce the stigma experienced by HIV+ women, and 3) reduce 
duplication of services and competition for scarce resources.28,29 However, integrating HIV 
and ANC services could also overburden already weak health systems by increasing work 
load, leading to poorer quality of care,30 and even higher attrition rates along the PMTCT 
cascade.31
Systematic reviews report a lack of robust evidence on the impact of integration on PMTCT 
service uptake and outcomes compared to non-integrated or partially integrated 
services.32,33 The aim of the Study of HIV and Antenatal care Integration in Pregnancy 
(SHAIP) cluster-randomized controlled trial was to determine if a comprehensive integrated 
approach to PMTCT and HIV treatment provision within ANC clinics improved service 
utilization and health outcomes in Nyanza Province, Kenya. In this manuscript we assess the 
effects of service integration on women’s and infants’ uptake of and retention in services 
along the PMTCT cascade.
Methods
Ethics
The SHAIP Trial was approved by the Institutional Review Boards of the University of 
California, San Francisco (UCSF) and the Kenya Medical Research Institute (KEMRI), as 
well as by the Associate Director for Science at the Centers for Disease Control and 
Prevention. All study participants gave written informed consent for the use of their de-
identified data. This trial is registered at clinicaltrials.gov NCT00931216.
Setting
The study took place in southern Nyanza Province (see Figure 1) during the period 2009–
2011. HIV prevalence in Nyanza Province was estimated to be 16% of reproductive aged 
women in 2008, more than double the national average.22 All sites were government health 
facilities receiving PEPFAR support through Family AIDS Care and Education Services 
(FACES) for both PMTCT and HIV treatment services.34
Study Design
We conducted a prospective cluster randomized trial comparing service utilization and 
health outcomes for HIV-infected women and their infants attending integrated ANC clinics 
with those attending non-integrated ANC clinics. Integrated clinics provided PMTCT and 
HIV care and treatment services (including highly active antiretroviral therapy [HAART]) 
within existing ANC services. The same clinic provided all prenatal and postpartum services 
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until a definitive pediatric HIV diagnosis was obtained or the child reached 18 months of 
age. At this time the woman and infant, if HIV infected, would be referred for long-term 
care to the facility’s HIV clinic. Non-integrated ANC clinics provided routine PMTCT 
services and referred HIV+ pregnant women to a separate HIV clinic at the same facility. 
Additional site details and study methods have been published previously.35
Randomization
Study sites were health facilities that provided ANC, PMTCT, and HIV services with ≥ 20 
new ANC clients per month. Facilities (n=12) were stratified as “Health Center/Dispensary” 
(smaller facilities, N = 8) or “Hospital” (larger sub-district/district hospitals, N = 4) and 
randomly allocated 1: 1 within strata to provide integrated or non-integrated services using 
ACluster software36 by the study’s biostatistician who was not involved in fieldwork. 
Clinics, healthcare providers, patients, and researchers involved in implementing the study 
were not blinded to the allocation.
Participants
The study population included all pregnant HIV+ women ≥ 18 years who were not enrolled 
in HIV care at baseline, as well as infants born to study participants.
Outcome Measures
The SHAIP Trial was powered to detect differences in the primary trial outcomes of MTCT 
and changes in maternal CD4 counts,35 which are reported elsewhere. Secondary PMTCT 
service utilization outcomes reported in this manuscript are presented below, with primary 
outcomes for the current analyses indicated in bold:
1. MTCT service provision (as documented in medical records)
• maternal ARV prophylaxis dispensed at baseline visit (Y/N)
• baseline CD4 count obtained (within 3 months of study enrollment) (Y/N)
• baseline WHO staging performed (Y/N)
• infant dried blood spot (DBS) HIV testing by 3 and 9 months of age 
(Y/N)
• time from date birth to first infant HIV test (days)
2. Maternal utilization of HIV services (as documented in medical records)
• enrollment in facility’s HIV care and treatment program within 12 
months of study enrollment (all HIV+ pregnant women were 
recommended to enroll in the program, regardless of HAART eligibility) 
(Y/N)
• time from baseline visit to enrollment in the HIV care and treatment program 
(days)
• HAART initiation among eligible women (CD4≤350 and/or WHO Stage 
III or IV) within 12 months of study enrollment (Y/N)
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• retention in HIV care (≥2 visits within 6 months of enrollment in care) (Y/N)
3. Adherence to PMTCT interventions during pregnancy, labor and delivery (L&D) 
and postpartum (postpartum maternal self-report)
• maternal ARV use during pregnancy (Y/N)
• delivery at a health facility (Y/N)
• ARV use during labor and delivery (Y/N)
• use of maternal and infant ARVs after the birth (Y/N)
• currently exclusively breastfeeding (Y/N)
Procedures
Healthcare providers at all study clinics received an initial week-long and periodic refresher 
trainings on high quality ANC, PMTCT, and HIV care service delivery provision as well as 
instruction on clinic logistics to improve service utilization for both models. ANC nurses at 
intervention sites received training on appropriate prescription and management of patients 
on HAART.
At all twelve ANC clinics, protocols mandated that all HIV-positive women should receive 
ARVs for PMTCT, WHO clinical staging and CD4 testing to determine HAART eligibility, 
as per national guidelines. Women received AZT/NVP/3TC to take at labor onset, 3TC/AZT 
post-delivery, and, if eligible, AZT.37 At intervention clinics, HIV+ women were offered 
enrollment and receipt of all HIV services at the ANC clinic, including HAART if eligible. 
ANC providers enrolled these women in longitudinal HIV care and managed their HIV care 
services and paperwork in the ANC clinic. At control clinics, ANC study staff encouraged 
all women to co-enroll in the facility’s separate HIV clinic and provided a referral form to 
facilitate enrollment. Women presented separately at these clinics, and HIV clinic providers 
handled HIV enrollment, paperwork, and care services.
The provision of PMTCT and HIV services followed Kenyan national guidelines in all sites 
for the duration of the study, with the only difference being the location of HIV services for 
pregnant and postpartum women (ANC clinic versus the HIV clinic). Guidelines 
recommended HAART initiation for HIV+ pregnant women at WHO clinical stage III or IV 
regardless of CD4 count, or WHO clinical stage I or II with CD4 count ≤ 350/mm3 
throughout the study period. In August 2010 all sites simultaneously implemented updated 
PMTCT national guidelines, recommending earlier ARV prophylaxis for pregnant women 
(at 14 weeks of pregnancy) and postpartum maternal/infant prophylaxis.
Data Collection Methods
Health facility staff members enter all patient socio-demographic and clinical data on paper 
forms and registers as part of routine clinic care services. Form data are then entered into an 
electronic database, which employs the Open Medical Record System (OpenMRS®) 
platform, by program data clerks. Routine programmatic paperwork at all study sites 
included a “Positive in Pregnancy” form completed at the first ANC visit or at HIV 
diagnosis, an HIV care enrollment form, HIV care follow-up visit forms, and two postnatal 
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forms: a “Motherhood” form for HIV+ postpartum women and an “HIV-Exposed Infant 
(HEI) Tracing Form” for infants who did not return to the clinic for HIV testing. Form data 
are linked using the pregnant woman’s ANC ID. Internal monitoring of data quality was 
conducted on a monthly basis by the study team, and the trial was also externally monitored.
Study staff abstracted data from this database for each SHAIP participant until 12 months 
after study enrollment. Completed postnatal forms were available for few study participants 
(173 [30%] intervention and 152 [25%] control) due to a variety of factors including women 
not returning to the clinic following delivery, incorrect contact addresses limiting tracing 
efforts, and incomplete reporting by busy clinicians.
Statistical Analysis
Statistical analysis was conducted using an intention-to-treat approach with all analyses 
adjusted for clustering of data within clinics. We compared participant baseline 
characteristics in the two study arms using chi-square and t-tests. Generalized Estimating 
Equations (GEE), which employed a logit transformation and assumed a binomial 
distribution, were used to compare dichotomous outcomes, with study arm (intervention or 
control) as the independent variable. GEE methods were used to account for repeated 
measures and clustering of data by site. We compared time-to-event outcomes across study 
arms using proportional hazards Cox regression. Multivariable analyses were not performed 
because there were no baseline variables that were significantly out of balance in the two 
arms, and exploratory analyses indicated that potential confounders (such as initial CD4 
count) did not confound the relationships between study arms and our key outcomes.
Missing data due to LTFU relative to the measurement of specific outcomes was a 
significant issue in this study that relied on routine health facility visits and program data. 
This especially affected analysis of postnatal PMTCT utilization data captured on the two 
postpartum forms (responses were available for only 325 [28%] of the original 1172 study 
participants). The amount of missing data varied by site, ranging from 37% to 90%. Thus, 
data on early uptake of infant testing (before 3 months) were only available for 720 (61%) of 
mother-infant pairs and the specific timing of early infant testing were only available for 664 
(57%) mother-infant pairs.
We used two methods to deal with missing data due to LTFU. First, we employed inverse 
probability of censoring weighting (IPCW) to account for potential bias associated with 
missing outcome data. We modeled the probability of remaining in the sample (P(c)) based 
on calendar time and baseline maternal characteristics (characteristics included in Table 1), 
then weighted the data (1/(P(c)) so that the distribution of maternal characteristics was 
similar to the observed baseline data. Second, we used estimates for cases with missing data 
for infant date of birth (DOB) or infant date of death. We estimated infant’s DOB using the 
woman’s estimated date of delivery (EDD). For infant death, we estimated the date of death 
at 1 month following the infant’s DOB (or the EDD if DOB was not available) based on the 
fact that the majority of infant deaths (60%) occur during the first month of life in Kenya.22 
Sensitivity analyses for maternal HIV care enrollment and infant testing uptake were also 
conducted by excluding maternal and (or) infant deaths and LTFU.
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Statistical analyses were conducted using Stata 12 for baseline, time-to-event, and initial 
bivariate analyses and SAS 9.3 for IPCW analyses.
Results
Participant baseline characteristics
A total of 1,172 HIV+ pregnant women enrolled in the study during June 2009–March 2011 
(Figure 2). No significant differences in participant baseline characteristics, i.e., age, 
education, marital status, gravity, parity, gestational age, mean CD4 count, WHO clinical 
stage, and HAART eligibility, were detected by study arm (Table 1).
Utilization of PMTCT cascade services by study arm
Table 2 shows women’s receipt/utilization of PMTCT cascade services by study arm. 
Receipt of prenatal PMTCT services, e.g., CD4 count, WHO staging, and ARVs for 
PMTCT, were similar in the two study arms.
HIV care enrollment was higher in intervention sites compared to control sites (69% versus 
36%, Odds Ratio (OR)=3.94, 95% Confidence Interval (CI): 1.14–13.63), and the median 
time to HIV care enrollment was significantly shorter among women in the intervention arm 
(0 versus 8 days, Hazard Ratio (HR)=2.20, 95% CI: 1.62–3.01). Although the number of 
HAART-eligible women identified at baseline was relatively small (n=214), women in the 
intervention arm were significantly more likely to have initiated HAART by study close 
compared to women in the control arm (40% in intervention compared to 17% in control, 
OR=3.22, 95% CI: 1.81–5.72). An additional 15 women in the intervention arm and 7 
women in the control arm (who were not HAART-eligible at baseline) became eligible and 
initiated HAART during the follow-up period.
Among the limited number of women with postpartum data (n=325), women in the 
intervention arm were more likely to report ARV use during pregnancy than those in the 
control arm (80% in intervention, compared to 49% in control, OR=4.05, 95% CI: 2.00–
8.00). However, women in the intervention arm were less likely to report ARV use during 
L&D (16% intervention versus 55% control; OR=0.16, 95%CI: 0.04–0.68), ARV use 
following delivery (13% intervention vs. 38% control; OR=0.24, 95%CI: 0.08–0.70), and 
infant ARV prophylaxis (29% intervention vs. 70% control; OR=0.18, 95%CI: 0.09–0.35) 
than women in the control arm. There were no statistically significant differences between 
the study arms in regards to the proportion of women reporting delivery in a health facility 
or exclusive breastfeeding (Table 2). Although the proportion of infants tested for HIV at 3 
and 9 months was slightly higher in the intervention arm, this did not achieve statistical 
significance. Figure 2 shows the proportion of women completing key cascade steps by 
study arm.
Sensitivity analyses
For initial analyses of maternal HIV care enrollment, we assumed that women did not enroll 
in HIV care if there was no HIV care documentation in the medical records. However, study 
participants might have enrolled elsewhere. As a sensitivity analysis, we repeated this 
Turan et al. Page 7













analysis excluding women lacking HIV care documentation in medical records and could 
not be located at the postpartum tracing visit. This analysis resulted in a lower magnitude 
OR of 1.94 (95% CI: 0.73–5.15) compared to the initial OR of 3.94 (95% CI: 1.14–13.63) 
for enrollment in HIV care. Similarly for infant testing uptake, we initially assumed that the 
absence of an infant HIV test result signified no HIV test. We conducted sensitivity analyses 
for the infant HIV testing uptake before 3 months of age excluding those LTFU. This 
resulted in an OR for infant HIV test of 1.31 (95% CI: 0.52 - 3.31), compared to the initial 
result 1.31 (95% CI: 0.48 - 3.58).
Analyses examining the impact of censoring revealed that adjustment for LTFU did not 
significantly change our results. Inverse probability of censoring weighting (IPCW) results 
were of similar direction, magnitude, and statistical significance to the initial results for 
variables that had substantial missing data (see the last two columns of Table 2).
Discussion
In this first cluster-randomized trial of ANC-HIV treatment integration in SSA, we found 
that integration had positive effects on some aspects of PMTCT service utilization, but not 
on others. Despite the convenience and benefits of being offered concurrent enrollment in 
ANC and HIV care, attrition of women and infants over the course of pregnancy and 
postpartum remained significant.
Initial services received by HIV+ pregnant women in ANC clinics were similar in both 
study arms. In both types of clinics, a high percentage of women were clinically staged and 
received ARVs for PMTCT. Intervention clinics noted improvements in HIV care 
enrollment, time to enrollment, and HAART initiation among eligible women compared to 
control clinics. These are clearly important benefits and correspond with previous non-
randomized integration study results.38–40 Given the advantages of early HAART initiation 
for PMTCT and maternal health,41 these important effects should not be taken lightly. 
However, the proportion of women with baseline CD4 count assessments was low in both 
arms (58% intervention and 54% control), although higher than in many other settings,8 
reflecting the logistical constraints affecting all sites in performing CD4 counts, e.g. stock-
outs of blood tubes and/or CD4 reagents. And the 70% HIV care enrollment, not 100%, at 
intervention sites indicates that women’s hesitations about initiating HIV care, regardless of 
location, continued to be a barrier for a substantial portion of women.
The self-reported PMTCT adherence data collected from women postpartum had 
inconsistent results. While there was significantly higher self-reported use of ARVs during 
pregnancy by women at intervention versus control sites, women from control sites were 
more likely to report ARV use during delivery and postpartum. However, the small number 
of study participants with completed postpartum forms (173 of 569 women in the 
intervention group and 152 of 603 women in the control group) make these results difficult 
to interpret. Early infant diagnosis was clearly inadequate in both arms of the study, and 
points to known challenges,42 including inadequate systems to identify HIV-exposed infants 
in postnatal clinics, insufficient resources to conduct home visits, and continuing stigma 
associated with HIV.43
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In our study women’s retention in HIV care was lower in the intervention arm than in the 
control arm (although not statistically significant). Similarly, a study in Mozambique found 
HIV patients attending integrated clinics in primary healthcare services had a higher risk of 
attrition six months after initiating treatment than HIV patients attending specialized HIV 
clinics.44 This questions if busy primary healthcare services have sufficient time and 
attention necessary to follow HIV clients and assure their retention when HIV services are 
absorbed. In addition, it has been noted that service integration cannot solve existing human 
resource shortages or problems of inadequate infrastructure.45 Service integration often 
results in increased provider workload, increased training needs, and even “organizational 
culture clash.”46 Alternatively women at control sites who followed through and enrolled in 
HIV care at a separate HIV clinic may have been more motivated than those who were more 
passively enrolled at the integrated sites.
Despite the benefits of integration seen, it is clear that we still have a long way to go to 
reduce gaps in the PMTCT cascade in low-resource settings. Other trials in SSA have also 
concluded that assuring women’s retention in care and adherence to PMTCT 
recommendations will reduce unacceptably high rates of vertical transmission.47 Integration 
of clinical services, although important, is probably not sufficient to address all the barriers 
to utilization of PMTCT services, including risks of stigma, discrimination, and violence.48 
An observational study conducted at a sub-set of SHAIP sites revealed that internalized 
HIV-related stigma was a significant issue for women in both integrated and non-integrated 
sites.49 A study conducted in Swaziland suggested that clients experienced more unwanted 
disclosure and risks of stigmatization at integrated versus non-integrated clinics.50
This real-world trial conducted in rural health facilities had a number of limitations. 
Although use of existing programmatic data as data sources in implementation science has 
been suggested as an efficient use of resources,51 we found that medical records and health 
facility registers were often incomplete and/or inconsistent. High rates of maternal and 
pediatric LTFU, coupled with inadequate completion of postpartum forms resulted in sparse 
data for some of our PMTCT cascade outcomes. It was also difficult to maintain a consistent 
level of service quality at the 12 government health facilities throughout the study duration. 
Insufficient and inconsistent staffing, supplies and systems may have affected fidelity to the 
site’s randomly assigned service model, the data availability, and outcomes of interest. 
Changes in national PMTCT guidelines during the study period (although implemented 
simultaneously at all study sites) also may have affected our results. The relatively small 
number of sites available for trial inclusion (12) combined with the realities of significant 
LTFU in the PMTCT cascade resulted in reduced power to detect statistically significant 
differences between the study arms for some outcomes. Actual intra-cluster correlation 
coefficients ranged from 0.10 (uptake of infant testing) to 0.28 (maternal HIV care 
enrollment), compared to the lower estimates that were used in sample size calculations. 
Lastly, demonstration of cost-effectiveness was not included in the design of this trial, but 
will be important to investigate as more programs around the world consider implementation 
of integrated ANC-HIV care services.
Based on preliminary results of this trial and other studies, several steps have been 
undertaken to address PMTCT cascade attrition in Kenya. A variety of interventions—
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including text message reminders, systems strengthening, community mobilization 
activities, and efforts to increase male involvement in ANC/PMTCT services—have been 
implemented to increase engagement of pregnant women in HIV care. Efforts are also 
underway to develop an integrated point-of-care electronic maternal and child health 
register, which will allow longitudinal follow-up and timely access to information on 
women and infants who fall out of care at each point in the PMTCT cascade. Option B+ 
(universal lifelong HAART for all HIV-positive pregnant women) is currently being scaled 
up in Kenya and is expected to increase uptake and retention in services.
Conclusions
In this study, we found that integration appears to have important advantages in terms of 
increasing HIV care enrollment of pregnant HIV+ women and earlier initiation of HAART. 
However, integration of clinical services may not be enough to retain women in long-term 
care or ensure infant testing and care. Further research focusing on improving systems and 
reducing key psycho-social barriers (including stigma) will be necessary in order to improve 
uptake and retention throughout the entire PMTCT cascade.
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Figure 1. Map showing distribution of study sites in Southern Nyanza
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Figure 2. Consort Diagram. The flow diagram of clusters and individuals through the cluster 
randomized trial
a The number of pregnant women known to be HIV-positive before the ANC visit may have 
been underestimated if some women who knew themselves to be HIV-positive did not 
disclose their status to the health worker and chose to undergo additional HIV testing for 
confirmation.
b The total number of HIV-positive women (known HIV-positives before the ANC visit plus 
those who tested HIV-positive during an ANC visit) may be underestimated, as these data 
were abstracted from routine ANC registers, which may not be complete. The need to rely 
on these different data sources resulted in lack of agreement for some totals presented in this 
figure.
c The number of women who declined to participate may be over-estimated, as some women 
who declined to participate in the study during their first ANC visit may have accepted study 
enrollment during a subsequent ANC visit.
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Figure 3. Elements of the PMTCT cascade completed for HIV-positive pregnant women 
attending intervention and control sites (proportions are based on all women enrolled in the 
study in each study arm)
* Only applicable for women who enrolled in HIV care
** Only applicable for women who were eligible for HAART
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